Literature DB >> 1473965

The complement system in xenotransplantation.

A P Dalmasso1.   

Abstract

The immediate barrier to xenotransplantation across phylogenetically distant species, a manifestation of natural immunity, is hyperacute rejection of the xenograft. Complement (C) plays a central pathophysiological role in hyperacute rejection. Hyperacute rejection is initiated when C is activated by natural antibodies against the vascular endothelium of the transplanted organ or by the endothelium itself. C activation fragments alone or in conjunction with natural antibodies set in motion a series of events in the vasculature of the xenogeneic organ which result in loss of endothelial functional integrity and fibrin deposition. This article reviews recent findings concerning the role of C in hyperacute rejection and evidence suggesting that inhibition of C activation may be a critical approach to avert hyperacute rejection.

Mesh:

Substances:

Year:  1992        PMID: 1473965     DOI: 10.1016/0162-3109(92)90020-d

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  9 in total

1.  Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection.

Authors:  L A Valdivia; J J Fung; A J Demetris; S Celli; F Pan; M Tsugita; T E Starzl
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

2.  Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.

Authors:  K Abu-Elmagd; S Todo; J Fung; J Demetris; J Rakela; A S Rao; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1994

3.  Crystal structure of the catalytic domain of human complement c1s: a serine protease with a handle.

Authors:  C Gaboriaud; V Rossi; I Bally; G J Arlaud; J C Fontecilla-Camps
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

Review 4.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

Review 5.  The biological basis of and strategies for clinical xenotransplantation.

Authors:  T E Starzl; L A Valdivia; N Murase; A J Demetris; P Fontes; A S Rao; R Manez; I R Marino; S Todo; A W Thomson
Journal:  Immunol Rev       Date:  1994-10       Impact factor: 12.988

6.  Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.

Authors:  L Bergamaschini; G Gobbo; S Gatti; L Caccamo; P Prato; M Maggioni; P Braidotti; R Di Stefano; L R Fassati
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 7.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

8.  A novel glycosphingolipid expressed in pig kidney: Gal alpha 1-3Lewis(x) hexaglycosylceramide.

Authors:  D Bouhours; J Liaigre; J Naulet; D Maume; J F Bouhours
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

Review 9.  Progress in Xenotransplantation: Immunologic Barriers, Advances in Gene Editing, and Successful Tolerance Induction Strategies in Pig-To-Primate Transplantation.

Authors:  Daniel L Eisenson; Yu Hisadome; Kazuhiko Yamada
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.